Navigation Links
Immtech Receives Listing Determination Letter
Date:4/2/2009

NEW YORK, April 2 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE AMEX: IMM) today announced that on March 27, 2009, the Company received notice from the NYSE Amex LLC (the "Exchange") indicating that the Exchange intends to initiate proceedings to delist the Company's common stock. The Company intends to appeal this determination and request an oral hearing before the Exchange's listing qualifications panel. Pursuant to Exchange rules, the delisting proceeding will be stayed pending the outcome of the Company's appeal, subject to the Exchange's on-going review of the Company's status.

Specifically, as previously disclosed, Immtech was notified on December 23, 2008 by the Exchange that the Company is not in compliance with the Exchange's requirements under Sections 1003(a)(ii), (iii) and (iv) of the Exchange's Company Guide.

There is no assurance that the Company's appeal will be successful. In the event that the Company's common stock is delisted by the Exchange, the Company believes that its common stock will be eligible to trade or be quoted on alternative markets.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. and subsidiaries (a development stage enterprise) is focused on global opportunities in the healthcare sector and opportunities in China. Immtech aims to leverage its established expertise and other assets in both new drug sales and enhanced healthcare-related services, including research and information-providing services, for developed and developing countries. For additional information, please visit the Company's website at http://www.immtechpharma.com.

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business which are not historical facts, are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2008 filed on June 18, 2008, and in its other SEC filings and include, but are not limited to: (i) conditions in the credit markets and the general economy; (ii) Immtech's ability to obtain additional funds; (iii) Immtech's ability to manage its remaining resources; (iv) Immtech's ability to continue as a going concern; (v) Immtech's ability to retain key personnel; (vi) the ability of Immtech's scientists and collaborators to discover new compounds; (vii) the availability of additional research grants; (viii) Immtech's ability to obtain regulatory approval of its drug candidates; (ix) the success of Immtech's clinical trials; (x) dependence upon and contractual relationship with partners; (xi) Immtech's ability to protect its intellectual property; and (xii) competition and alternative technologies.

In addition, Immtech does not undertake any obligation, and specifically disclaims any obligation to publicly update or revise forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Immtech To Reschedule Quarterly Conference Call
2. Immtech Reports Fiscal Third Quarter 2009 Results
3. Immtech Announces Sale of Property Subsidiary in China
4. Immtech Receives Listing Notice From NYSE Alternext US
5. Immtech Reports Fiscal Second Quarter 2009 Results
6. Immtech Investor Conference Call Scheduled for June 25, 2008
7. Immtech Reports Fiscal Year End 2008 Results
8. Immtech Announces Results From Hepatitis C Discovery Program
9. Immtech Announces Update on Business Operations
10. Immtech Investor Conference Call Scheduled for February 22, 2008
11. Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
(Date:6/24/2016)... ... ... Finally, a bruise cream that really works. Originally designed to reduce ... post-surgical treatment plans of a variety of other procedures including, but not limited to, ... bruising and causes a rapid resolution of bruising and inflammatory changes compared to no ...
(Date:6/24/2016)... ... 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona has re-located to ... vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new retreat center ... as well as the Sedona Rouge, both popular accommodations for SpiritQuest clients. The ...
(Date:6/23/2016)... ... 23, 2016 , ... vcfo, a consulting firm that provides ... announce the promotion of Mike Mackey to Regional Vice President of Southeast Texas. ... responsible for managing client projects and overseeing vcfo financial consultants in the Houston ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology: